Simplex Trading
BCLI

Simplex Trading’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Simplex Trading’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-693
Closed -$3K – 8469
2024
Q2 		$3K Buy
+693
New +$5.2K ﹤0.01% 8072
2024
Q1 		– Sell
-413
Closed -$1K – 8835
2023
Q4 		$1K Sell
413
-194
-32% -$581 ﹤0.01% 8432
2023
Q3 		$1K Sell
607
-3,780
-86% -$85.9K ﹤0.01% 8247
2023
Q2 		$135K Buy
4,387
+2,087
+91% +$86.5K ﹤0.01% 4730
2023
Q1 		$113K Sell
2,300
-2,207
-49% -$64K ﹤0.01% 5012
2022
Q4 		$110K Sell
4,507
-453
-9% -$16.9K ﹤0.01% 4950
2022
Q3 		$328K Sell
4,960
-853
-15% -$42.8K ﹤0.01% 3969
2022
Q2 		$240K Buy
5,813
+2,473
+74% +$111K ﹤0.01% 4389
2022
Q1 		$168K Sell
3,340
-6,800
-67% -$334K ﹤0.01% 5399
2021
Q4 		$608K Sell
10,140
-1,147
-10% -$56.5K ﹤0.01% 3537
2021
Q3 		$641K Hold
11,287
– – ﹤0.01% 3722
2021
Q2 		$643K Buy
11,287
+11,164
+9,076% +$596K ﹤0.01% 3768
2021
Q1 		$708K Sell
123
-49
-28% -$3.7K ﹤0.01% 2864
2020
Q4 		$1.17M Buy
172
+91
+112% +$12.4K ﹤0.01% 2363
2020
Q3 		$2.04M Buy
81
+36
+80% +$7.37K ﹤0.01% 1508
2020
Q2 		$748K Sell
45
-70
-61% -$7.55K ﹤0.01% 2424
2020
Q1 		$798K Buy
115
+113
+5,650% +$8.82K ﹤0.01% 2097
2019
Q4 		$9K Sell
2
-3
-60% -$174 ﹤0.01% 6417
2019
Q3 		$28K Buy
+5
New +$295 ﹤0.01% 5541
2019
Q2 		– Sell
-1
Closed -$58 – 6724
2019
Q1 		$9K Hold
1
– – ﹤0.01% 6193
2018
Q4 		$7K Buy
+1
New +$49 ﹤0.01% 6034
2017
Q3 		– Sell
-14
Closed -$3K – 5889
2017
Q2 		$3K Buy
14
+2
+17% +$123 ﹤0.01% 4919
2017
Q1 		$3K Buy
+12
New +$625 ﹤0.01% 4930

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading's BCLI Position: Q4 2024 in Review

Simplex Trading sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 77 shares.

Simplex Trading first reported a position in BCLI in Q3 2015 and held it in 25 quarters. The position peaked at $605K in Q1 2023. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • Simplex Trading reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • Simplex Trading sold 77 BRAINSTORM CELL THERAPUTC shares in Q4 2024.
  • Simplex Trading first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2015 and held it in 25 quarters.
  • Simplex Trading's BRAINSTORM CELL THERAPUTC position peaked at $605K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on Simplex Trading's 13F filing for Q4 2024, filed 11 Feb 2025.